Drug intelligence / Profile preview

AC01

Development stage: Phase 2
Lead developer: AnaCardio
Modality: Small Molecules, Peptides
Administration: Oral

Overview

AC01 is an oral ghrelin peptidomimetic small-molecule developed by AnaCardio AB, in-licensed from Helsinn, for the treatment of heart failure with reduced ejection fraction (HFrEF). It acts as a calcium sensitizing inotrope by agonizing the ghrelin/growth hormone secretagogue receptor (GHSR), thereby increasing cardiac contractility and force without the safety concerns associated with conventional inotropes that increase calcium concentrations and flux. This unique mechanism aims to improve cardiac output and potentially offer disease-modifying effects for HFrEF patients.

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on AC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC01.

Explore the full profile